Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Hansa Biopharma AB ( (SE:HNSA) ) just unveiled an update.
Hansa Biopharma will showcase its leadership in immunomodulatory therapies at the H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq in New York. COO and U.S. President Maria Törnsén is scheduled for a fireside chat on May 19, 2026, alongside H.C. Wainwright senior healthcare analyst Douglas Tsao.
The appearance underscores Hansa’s efforts to engage the investor community as it advances its IgG-cleaving enzyme technology and commercial portfolio. Increased visibility at a high-profile investor forum may support the company’s capital markets profile and highlight progress in areas such as kidney transplantation and Guillain-Barré Syndrome.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK103.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing novel immunomodulatory therapies for acute and complex immune disorders. Leveraging its proprietary IgG-cleaving enzyme platform, the company targets serious unmet needs in transplantation, gene therapy and autoimmune diseases, with products such as imlifidase and its next-generation candidate HNSA-5487. Based in Lund, Sweden, Hansa operates in Europe and the U.S. and is listed on Nasdaq Stockholm under the ticker HNSA.
Average Trading Volume: 368,061
Technical Sentiment Signal: Strong Sell
Current Market Cap: SEK2.9B
For detailed information about HNSA stock, go to TipRanks’ Stock Analysis page.